Institution identification

PURI

https://redirect.ema.europa.eu/resource/44487

Institution ID

44487

Institution full name and acronym

Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina

Institution countries

Italy

Type of institution

Educational Institution
Hospital/Clinic/Other health care facility

ENCePP partner

Yes
Institution description
The Centre is responsible for collecting and analyzing spontaneous reports of ADR from all over Sicily since 2003. The database include data from 1996. We collaborate with the National Authority (Agenzia Italiana del Farmaco - AIFA) for signal detection and Other national/international initiatives concerning drug safety. The Centre has also expertises in the field of pharmacoepidemiology,drug information and drug utilization,several studies are conducted using prescription data from GPs Electronic Health Records. Overall,about 10 people are actively involved in these topics at different levels.
Institution details
Experience with collecting data directly from individual patients or respondents:
Yes
Interest in carrying out research that is funded by pharmaceutical companies:
No

Contact

Studies conducted by the institution

ACCESS template protocol for safety of COVID-19 vaccines
Background rates of Adverse Events of Special Interest for monitoring COVID-19 vaccines (ACCESS-BGR)
Dulaglutide Modified-Prescription-Event Monitoring Study and network database study: a multi-database collaborative research program of observational studies to monitor the utilisation and safety of dulaglutide in the EU
Pattern of use of incretin-based drugs in clinical practice
Rapid Safety Assessment of SARS-CoV-2 vaccines in EU Member States using electronic health care datasources (CVM Covid19-Vaccine-Monitor-EHR)
Surveillance of Adverse Event related to childhood vaccination reported by parents
The BRodalumab Assessment of Hazards: A Multinational Safety (BRAHMS) study in electronic healthcare databases
Time to treatment intensification in patients receiving metformin+incretin-based medicines versus metformin+other hypoglicemics (Time to treatment intensification with incretins)